We are very excited to announce MND NSW and MND Australia will have a combined team in this year's City2Surf. We have limited spots available for the Charity Superstar entries. As a Charity Superstar you will receive free entry to the City2Surf, a starting position in front of the pack, merchandise and lots more. Commit to raising $1,000 today and join us for the 2019 City2Surf. Visit https://fairfaxconsole.com.au/city2surf2019/motor-neurone-disease-mnd-association-of-nsw/request
Congratulations Forbes! Our biggest Walk yet with 180 participants and $15,276 raised to date. A huge thank you to all our participants, fundraisers and amazing sponsors, Duncan Stockcrates, Grand Ridge Brewery, Anytime Fitness, Bernardi's Farmers Market, Lions Club and the wonderful support from Forbes Shire Council.
Our members and their families are always welcome to call in and see us here at Gladesville. It is often a good opportunity to sit and chat as well as to find out a bit more about what we do here at MND NSW and just what we offer to our members.With that in mind we thought we would set a regular time for people to call in and see us for a coffee and a chat. Nothing formal, but there will be members of our team here who will be able to answer questions if you have them or to just make you a coffee or tea and have a social chat. It is also a great opportunity for people who are just learning about MND to come and connect with us.
A device the size of a small paperclip, created to give people with severe paralysis the ability to communicate again, has been approved for its first-in-human clinical trial - an early feasibility study (EFS) of the safety of the device - at The Royal Melbourne Hospital. Five patients, living within two hours of Melbourne, with a range of conditions including spinal cord injury, stroke, muscular dystrophy, or motor neurone disease, including amyotrophic lateral sclerosis (ALS) will be recruited during 2019 to trial the device.
The medication riluzole, which is often prescribed to people with motor neurone disease, is now available in liquid form under the Pharmaceutical Benefits Scheme (PBS). Riluzole is anti-glutamate medication that appears to block the release of glutamate from nerve cells (neurones) and for people with the most common forms of MND it probably prolongs median survival by two to three months (median is the mid-point – half those taking riluzole have survival prolonged by more than two to three months).
